Fabry disease sales will grow through 2036, led by enzyme replacement therapy at 27.9% of the treatment segment in 2026, driven by high adoption across primary application categories. The market was valued at USD 2.40 billion in 2025 and is expected to be worth USD 5.60 billion by 2036.